Table 1.
EC50 of hesperadin against a panel of influenza A and B viruses.
| Influenza Strains | Drug Sensitivity | EC50 (µM) a | SI b |
|---|---|---|---|
| A/Texas/4/2009 (H1N1) | 1.07 ± 0.11 | 19.9 | |
| A/North Carolina/39/2009 (H1N1) | 0.82 ± 0.02 | 26 | |
| A/Washington/29/2009 (H1N1) | Amantadine Resistant | 0.37 ± 0.12 | 57.6 |
| A/California/02/2014 (H3N2) | Oseltamivir Resistant | 1.80 ± 0.42 | 11.8 |
| A/Texas/12/2007 (H3N2) | 2.21 ± 0.23 | 9.7 | |
| A/WSN/1933 (H1N1) | Amantadine Resistant | 0.22 ± 0.04 | 56.1 |
| A/California/07/2009 (H1N1) | Oseltamivir Sensitive | 0.28 ± 0.03 | 76.1 |
| B/Wisconsin/1/2010 (Yamagata) | Amantadine Resistant | 0.73 ± 0.05 | 29.2 |
| B/Brisbane/60/2008 (Victoria) | Oseltamivir Sensitive | 0.52 ± 0.05 | 41 |
a All EC50 results were determined in plaque assays in duplicates using the ST6Gal I-overexpressing MDCK cells (AX-4) [26] in 6-well plates; The EC50 value represents the average of two repeats ± standard deviation; b SI refers to the selectivity index, which is calculated by dividing the 48 h CC50 of hesperadin by the EC50 of hesperadin.